Cambridge Heart Reports Preliminary Results for the Three and Six Months Ended June 30, 2012

Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today reported preliminary revenue results for the three and six months ended June 30, 2012. Revenue for the second quarter is expected to total $450,000 compared to $542,000 in the prior year, and revenue for the six-month period is expected to total $1,004,000 compared to $1,179,000 in the same six-month period in 2011.

The Company also announced that it has restructured its operations in order to reduce its cash burn. The restructuring includes significant reductions in personnel and overhead costs across all functions of the Company, in addition to management agreeing to restructure its compensation. The new organizational structure, which is projected to reduce the quarterly operating expenses by approximately $935,000, allows the Company to continue to support its existing customer base and distribution partnerships while it executes on certain key activities and explores strategic alternatives. The Company estimates its average quarterly cash burn going forward will be approximately $300,000. At June 30, 2011, the Company’s cash balance was $420,000.

“While we have achieved certain objectives in executing on our OEM strategy, the financial results have been well below our projections prompting the decision to take steps to reduce our operating expenses” said Ali Haghighi-Mood, President and Chief Executive Officer of Cambridge Heart. “This scaled down organizational structure will provide us additional time to continue our efforts towards the Company’s stated commercial objectives as we seek additional financing and explore other strategic alternatives. On behalf of the Board of Directors and the management team, I would like to thank all of the employees that were affected by this restructuring for their service and commitment to the Company.”

The Company’s management is in discussion with holders of its secured convertible promissory notes (the “Notes”) regarding the exercise of the additional investment rights (the “AIRs”) issued to the Note holders in connection with the Company’s 2012 financing. The AIRs, which currently expire on July 15, 2012, would bring an estimated $873,000 in gross proceeds if fully exercised. The Company believes that this amount, in addition to the existing cash and projected revenue, would provide up to twelve months of operating capability.

Cambridge Heart addresses a key problem in cardiac diagnosis – the identification of those at risk of sudden cardiac death. Sudden cardiac arrest (SCA) accounts for approximately one fourth of all cardiac deaths, or approximately 300,000 deaths, in the United States each year – more than lung cancer, breast cancer and HIV/AIDS combined. Out-of-hospital survival is less than 8%, making prediction and prevention critically important. It is estimated that there are approximately 10 to 12 million heart attack and heart failure patients in the U.S. who can benefit from annual Microvolt T-Wave Alternans (MTWA) testing. MTWA is a marker of SCA risk which is measured during a non-invasive treadmill test using Cambridge Heart’s proprietary technologies. The Company’s MTWA test is the only one of its kind that is reimbursed by Medicare under a National Coverage Policy.

Questions can be directed to the Company's management or its investor relations firm at the contact numbers provided.

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company's products incorporate proprietary Microvolt T-Wave Alternans^™ (MTWA) measurement technologies, including the patented Analytic Spectral Method^® and ultrasensitive disposable electrode sensors. The Company's MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.

Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB. For additional information, please refer to the Company's website at: http://www.cambridgeheart.com.

Statements contained in this press release that are not purely historical are forward-looking statements. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could", and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties. Forward-looking statements include statements about the Company's belief that it will be able to maintain support of its existing customer base, international distributor network and OEM partner, and that proceeds from the full exercise of the AIR and projected revenue would provide up to twelve months of additional operating capability. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to obtain funding necessary to fund operations and to develop or enhance our technology, adverse results in future clinical studies of our technology, material deviations from our current operating plan, lower than expected sales, failure to obtain or maintain adequate levels of government and third-party reimbursement for use of our MTWA test, customer delays in making final buying decisions, decreased demand for our products, failure to obtain or maintain patent protection for our technology, overall economic and market condition and other factors identified in our most recent Annual Report on Form 10-K under “Risk Factors”, which is on file with the SEC and available at www.sec.gov. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.